Cell Source, Inc. (CLCS)

Market Cap	30.84K
Revenue (ttm)	n/a
Net Income (ttm)	-5.61M
Shares Out	38.55M
EPS (ttm)	-0.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	119
Open	0.0008
Previous Close	0.0002
Day's Range	n/a
52-Week Range	0.0002 - 0.7400
Beta	-155.11
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About CLCS

Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company’s Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: CLCS